Browse hierarchy: [Microbiology (MI)](/submissions/MI) → [Subpart D — Serological Reagents](/submissions/MI/subpart-d%E2%80%94serological-reagents) → [21 CFR 866.3370](/submissions/MI/subpart-d%E2%80%94serological-reagents/866.3370) → NDZ — Assay, Nucleic Acid Amplification, Growth Identification, Mycobacterium Tuberculosis

# NDZ · Assay, Nucleic Acid Amplification, Growth Identification, Mycobacterium Tuberculosis

_Microbiology · 21 CFR 866.3370 · Class 1_

**Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/NDZ

## Overview

- **Product Code:** NDZ
- **Device Name:** Assay, Nucleic Acid Amplification, Growth Identification, Mycobacterium Tuberculosis
- **Regulation:** [21 CFR 866.3370](/submissions/MI/subpart-d%E2%80%94serological-reagents/866.3370)
- **Device Class:** 1
- **Review Panel:** [Microbiology](/submissions/MI)
- **3rd-party reviewable:** yes

## Identification

Mycobacterium tuberculosis immunofluorescent reagents are devices that consist of antisera conjugated with a fluorescent dye used to identify Mycobacterium tuberculosis directly from clinical specimens. The identification aids in the diagnosis of tuberculosis and provides epidemiological information on this disease. Mycobacterium tuberculosis is the common causative organism in human tuberculosis, a chronic infectious disease characterized by formation of tubercles (small rounded nodules) and tissue necrosis (destruction), usually occurring in the lung.

## Classification Rationale

Class I (general controls).

## Recent Cleared Devices (1 of 1)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [K000884](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/NDZ/K000884.md) | BD PROBETEC ET MYCOBACTERIUM TUBERCULOSIS COMPLEX (CTB) CULTURE IDENTIFICATION ASSAY | Becton Dickinson Biosciences | Jan 19, 2001 | SESE |

## Top Applicants

- Becton Dickinson Biosciences — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/NDZ](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/NDZ)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com